0001410939-22-000024.txt : 20220322
0001410939-22-000024.hdr.sgml : 20220322
20220322164449
ACCESSION NUMBER: 0001410939-22-000024
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220318
FILED AS OF DATE: 20220322
DATE AS OF CHANGE: 20220322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carroll David Francis
CENTRAL INDEX KEY: 0001703623
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36080
FILM NUMBER: 22760220
MAIL ADDRESS:
STREET 1: ONE UNIVERSITY SQUARE DRIVE, SUITE 280
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IVERIC bio, Inc.
CENTRAL INDEX KEY: 0001410939
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208185347
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: (609) 474-6755
MAIL ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Ophthotech Corp.
DATE OF NAME CHANGE: 20070828
4
1
wf-form4_164798186621560.xml
FORM 4
X0306
4
2022-03-18
0
0001410939
IVERIC bio, Inc.
ISEE
0001703623
Carroll David Francis
C/O IVERIC BIO, INC.
8 SYLVAN WAY
PARSIPPANY
NJ
07054
0
1
0
0
CFO
Common Stock
2022-03-18
4
M
0
8237
1.45
A
74505
D
Common Stock
2022-03-18
4
S
0
11561
17.0022
D
62944
D
Stock Option (right to buy)
1.45
2022-03-18
4
M
0
8237
0
D
2028-12-11
Common Stock
8237.0
91763
D
The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2021.
This total includes 764 shares acquired by the Reporting Person on March 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported.
The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on March 18, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
This stock option award was granted on December 12, 2018 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.
/s/ Todd Anderman, as Attorney-in-Fact for David Carroll
2022-03-22